Gordon KB - Search Results

1

A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.

Gordon KB, Leonardi CL, Lebwohl M, Blauvelt A, Cameron GS, Braun D, Erickson J, Heffernan M. Gordon KB, et al. J Am Acad Dermatol. 2014 Dec;71(6):1176-82. doi: 10.1016/j.jaad.2014.07.048. Epub 2014 Sep 19. J Am Acad Dermatol. 2014. PMID: 25242558 Clinical Trial.

2

Biologic therapy for psoriasis: the new therapeutic frontier.

Singri P, West DP, Gordon KB. Singri P, et al. Among authors: gordon kb. Arch Dermatol. 2002 May;138(5):657-63. doi: 10.1001/archderm.138.5.657. Arch Dermatol. 2002. PMID: 12020229

3

The immunology of psoriasis and biologic immunotherapy.

Mehlis SL, Gordon KB. Mehlis SL, et al. Among authors: gordon kb. J Am Acad Dermatol. 2003 Aug;49(2 Suppl):S44-50. doi: 10.1016/s0190-9622(03)01134-4. J Am Acad Dermatol. 2003. PMID: 12894125 Review.

4

Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis.

Gottlieb AB, Gordon KB, Lebwohl MG, Caro I, Walicke PA, Li N, Leonardi CL; EFALIZUMAB STUDY GROUP. Gottlieb AB, et al. Among authors: gordon kb. J Drugs Dermatol. 2004 Nov-Dec;3(6):614-24. J Drugs Dermatol. 2004. PMID: 15624744 Clinical Trial.

5

Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.

Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, Walicke PA, Compton PG, Gottlieb AB; Efalizumab Study Group. Leonardi CL, et al. Among authors: gordon kb. J Am Acad Dermatol. 2005 Mar;52(3 Pt 1):425-33. doi: 10.1016/j.jaad.2004.09.029. J Am Acad Dermatol. 2005. PMID: 15761420 Clinical Trial.

6

The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques.

Gordon KB, Bonish BK, Patel T, Leonardi CL, Nickoloff BJ. Gordon KB, et al. Br J Dermatol. 2005 Nov;153(5):945-53. doi: 10.1111/j.1365-2133.2005.06816.x. Br J Dermatol. 2005. PMID: 16225604 Clinical Trial.

7

Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy.

Gordon KB, Gottlieb AB, Leonardi CL, Elewski BE, Wang A, Jahreis A, Zitnik R. Gordon KB, et al. J Dermatolog Treat. 2006;17(1):9-17. doi: 10.1080/09546630500472838. J Dermatolog Treat. 2006. PMID: 16467018 Free article. Clinical Trial.

8

Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis.

Papp KA, Miller B, Gordon KB, Caro I, Kwon P, Compton PG, Leonardi CL; Efalizumab Study Group. Papp KA, et al. Among authors: gordon kb. J Am Acad Dermatol. 2006 Apr;54(4 Suppl 1):S164-70. doi: 10.1016/j.jaad.2005.10.032. J Am Acad Dermatol. 2006. PMID: 16488338 Clinical Trial.

9

Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I.

Pariser DM, Gordon KB, Papp KA, Leonardi CL, Kwon P, Compton PG, Rundle AC, Walicke PA, Lebwohl M. Pariser DM, et al. Among authors: gordon kb. J Cutan Med Surg. 2005 Dec;9(6):303-12. doi: 10.1007/s10227-005-0116-1. J Cutan Med Surg. 2005. PMID: 16699904 Review.

10

Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial.

Papp KA, Bressinck R, Fretzin S, Goffe B, Kempers S, Gordon KB, Caro I, Walicke PA, Wang X, Menter A; Efalizumab Study Group. Papp KA, et al. Among authors: gordon kb. Int J Dermatol. 2006 May;45(5):605-14. doi: 10.1111/j.1365-4632.2006.02777.x. Int J Dermatol. 2006. PMID: 16700803 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

192 results

Search Page

Filters